Gastroenterology

Brand Name
Description
Ocaliva®
(obeticholic acid)
Ocaliva® is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA
Brand Name
Description
Linzess®
(linaclotide)
Linzess® is a guanylate cyclase-C agonist indicated in adults for treatment of Irritable bowel syndrome with constipation. (IBS-C) and Chronic idiopathic constipation. (CIC)
Pylera®
(bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride)
Pylera® is indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease to eradicate H. pylori.
  • THE MEDICAL INFORMATION AVAILABLE ON THIS WEBSITE IS FOR GENERAL INFORMATION ONLY AND IS NOT A SUBSTITUTE OR REPLACEMENT FOR A MEDICAL CONSULTATION, NOR DOES IT CONSTITUTE ADVICE, RECOMMENDATION OR SUGGESTION FOR SELF-PRESCRIPTION OR SELF-MEDICATION.
  • USERS SHOULD NOT USE THIS INFORMATION TO ASSESS, DIAGNOSE OR TREAT ANY MEDICAL COMPLAINT AND PATIENTS MUST SEEK PROFESSIONAL ADVICE FROM A QUALIFIED PHYSICIAN BEFORE TAKING ANY ACTION IN RESPECT OF INFORMATION PROVIDED ON THIS WEBSITE.
  • THE AVAILABILITY OF PRODUCTS MARKETED BY NEWBRIDGE MAY VARY BY COUNTRY AND YOU MUST CHECK WITH YOUR LOCAL REGULATORY AUTHORITIES FOR RELEVANT INFORMATION OR VARIATIONS.
  • THIS WEBSITE CONTAINS INFORMATION ABOUT MEDICINAL PRODUCTS REGISTERED REGIONALLY NOT ALL OF THE PRODUCTS AND/OR INDICATIONS THAT ARE MENTIONED ON THE WEBSITE OF NEWBRIDGE ARE AVAILABLE IN ALL THE MARKETS, AS SOME OF THESE PRODUCTS ARE CURRENTLY UNDER REGISTRATION ACROSS THE MENA REGION AND ARE SUBJECT TO APPROVAL ACCORDING TO LOCAL LAWS AND REGULATIONS, AND/OR MAY BE MARKETED BY COMPANIES OTHER THAN NEWBRIDGE PHARMACEUTICALS
  • PLEASE REFER TO YOUR LOCAL NEWBRIDGE PHARMACEUTICAL SATELLITE OFFICE TO ADVISE ON THE AVAILABILITY OF THESE PRODUCTS AND REFER TO COUNTRY SPECIFIC LOCALLY APPROVED PRESCRIBING INFORMATION FOR MORE DETAILS ON THE PRODUCT AND INDICATIONS IN YOUR COUNTRY. THE INFORMATION INCLUDED IN THIS WEBSITE IS NOT INTENDED TO CONSTITUTE PROMOTION IN ANY MANNER OF ANY OF THE DRUGS REFERENCED.
  • THE INFORMATION POSTED ON THIS WEBSITE IS PROVIDED FOR GENERAL INFORMATION PURPOSES ONLY. WHILST NEWBRIDGE PHARMACEUTICALS WILL MAKE EVERY REASONABLE EFFORT TO INCLUDE ACCURATE AND UP-TO-DATE INFORMATION, WE SHALL NOT HOWEVER BE LIABLE IN ANY WAY FOR ERRORS OR OMISSIONS IN THE CONTENTS OF THIS WEBSITE. ALL INFORMATION IS PROVIDED "AS IS". CONSEQUENTLY, THE INFORMATION SHOULD BE CAREFULLY EVALUATED BY SITE VISITORS AND NEWBRIDGE PHARMACEUTICALS DOES NOT PROVIDE ANY WARRANTIES ABOUT COMPLETENESS OR ACCURACY OF THE INFORMATION ON THIS WEBSITE OR ITS POSSIBLE USES.
  • THIS WEBSITE CONTAINS LINKS TO THIRD PARTIES' PAGES OR WEBSITES AND NEWBRIDGE PHARMACEUTICALS MAKES NO REPRESENTATION, NOR DOES IT HAVE ANY RESPONSIBILITY IN RELATION TO ANY MATERIAL OR INFORMATION YOU OBTAIN FROM ANY SUCH PAGES OR WEBSITES.